ERITROPOYETINA EN IRC PDF

Eritropoyetina, insuficiencia renal crónica y cáncer .. A insuficiência renal crônica (IRC) é uma enfermidade que provoca a perda parcial ou total da função . Métodología de cuantificación de eritropoyetina. Uploaded . La administración de eritropoyetina Beta y muestras de sangre de todos los . IRC Mecanismos. Los riñones sanos producen una hormona llamada eritropoyetina (EPO). La EPO envía una señal al cuerpo para que produzca más células rojas sanguíneas.

Author: Nitilar Nalabar
Country: Guadeloupe
Language: English (Spanish)
Genre: Life
Published (Last): 3 March 2010
Pages: 211
PDF File Size: 20.28 Mb
ePub File Size: 9.45 Mb
ISBN: 501-5-84091-867-4
Downloads: 42576
Price: Free* [*Free Regsitration Required]
Uploader: Ball

Are you a health professional able to prescribe or dispense drugs? You can change the settings or obtain more information by clicking here.

Previous article Next article. New indications for erythropoietin in clinical practice.

eritropoyetina en irc pdf

July Pages Although the cause is multi-factorial, the most known is inadequate erythropoietin production. Print Send to a friend Export reference Mendeley Statistics.

From Monday to Friday from 9 a. Anemia has been associated with poor prognosis in patients with several conditions such as cancer, chronic kidney disease and congestive heart failure. This item has received. To improve our services and products, we use “cookies” own or third parties authorized reitropoyetina show advertising related to client preferences through the analyses of navigation customer behavior.

  ENCEFALITIS ESPONGIFORME PDF

Subscribe to our Newsletter. Complexo Hospitalario Universitario Juan Canalejo. The utilization of rHuEp changed definitively the treatment and the natural history of anemia in patients with chronic renal insufficiency CRIand now is modifying the treatment of anemia of other non-renal patients as anemia of premature, anemia in onco-hematological illnesses, anemia in human immunodeficiency virus HIV infection, and for reduction of allogenic blood transfusions in surgery.

SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal’s impact.

Causas de respuesta ineficaz a la ertiropoyetina recombinante.

INSUFICIENCIA RENAL CRONICA-UCI by Oscar Antonio Urrego Rivera on Prezi

Si continua navegando, consideramos que acepta su uso. In randomized editropoyetina, the achievement of normal or nearly normal hemoglobin levels is not associated with improved survival and reduced cardiovascular risk; however the ideal hemoglobin level with the use of erythropoiesis-stimulating agents seems to be problematic.

Universidad de Santiago de Compostela. We analyze briefly the clinical indications of rHuEpo and the possible complications secondary to its use. Anemia is almost unavoidable in the last stages of chronic kidney disease. Nine issues are published each year, including mostly originals, reviews and consensus documents. Show more Show less. SRJ is a prestige metric based on the idea that not all citations are the same.

More information is needed in order to obtain definite conclusions; in the meantime, using the lowest possible dose of erythropoietin seems to be the most prudent approach.

  GENDER LANGUAGE AND DISCOURSE ANN WEATHERALL PDF

Síntomas, causas y tratamientos de la anemia – American Kidney Fund (AKF)

The journal fully endorses the goals of updating knowledge and facilitating the acquisition of key developments in internal medicine applied to clinical practice. Subscriber If you already have your login data, please click here. Indicaciones de la eritropoyetina recombinante. CiteScore measures average citations received per document published.

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two receding years. SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

Continuing navigation will be considered as acceptance of this use. Treatment with erythropoiesis-stimulating agents, such as erythropoietin, is a logical strategy that has enabled clinical improvement and reduced transfusion requirements for the patients; however, total correction of anemia with erythropoiesis-stimulating agents has demonstrated an increase in the risk of mortality or cardiovascular complications associated with these agents.